Concord Biotech Unit II Passes USFDA Inspection with Minor Observation

Concord Biotech announced the successful conclusion of a USFDA inspection at its Unit II formulation facility in Valthera, Gujarat. The inspection resulted in a single minor procedural observation, which is not related to Good Manufacturing Practices (GMP). The company will submit a comprehensive response to this observation within the stipulated timeline. Concord Biotech does not anticipate any material impact on its current business operations or existing supplies from this facility due to this development. The USFDA has issued one minor observation which is procedural in nature and not related to GMP.